ClinicalTrials.gg
Active, not recruitingNCT03228459ILERVASUpdated Mar 27, 2026

The ILERVAS Project: Assessing the Prevalence of Subclinical Vascular Disease and Hidden Kidney Disease

An interventional study of Dried blood spot test and Urine test in Atherosclerosis, Chronic Kidney Diseases and Metabolic Syndrome, sponsored by Institut de Recerca Biomèdica de Lleida. Active, not recruiting at 3 sites in Spain. Open to participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Institut de Recerca Biomèdica de Lleida · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Jan 2015, registered Jul 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16,660
Allocation
Randomized
Ages
45 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 61 studies in Atherosclerosis with a site in Spain — 10 open to participants now, 25 under way, 12 of them phase 3. Atherosclerosis · Spain.

Enrollment
6th of 41
16,660 · median 969
Started
2015
with 1 other
No phase
12 of 61
none open now
Primary completion
2018-12
later than 0 of 24 live
Registered
23rd of 61
by date

Among the 61 studies in Atherosclerosis with a site in Spain, this one is the 6th largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2015, is one of 12 with no phase, reaches primary completion later than 0 of the 24 other live ones, and was the 23rd registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

10 of the 61 studies in Atherosclerosis with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 45 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Atherosclerosis with a site in Spain, or all of them as a file.
02

Study summary

BACKGROUND AND OBJECTIVES:

Cardiovascular disease is the leading cause of death despite huge primary and secondary prevention policies with a strong economic burden. The primary objectives of the ILERVAS project are: (i) to identify unknown factors involved in the presence of atherosclerosis, metabolic syndrome, pre-diabetes and hidden kidney disease in a low/moderate cardiovascular risk population; (ii) to identify unknown factors involved in the progression of atherosclerosis, metabolic syndrome, pre-diabetes and hidden kidney disease in a low/moderate cardiovascular risk population; (iii) to Assess of the impact of arterial ultrasound on cardiovascular events and mortality in a low/moderate cardiovascular risk population.

METHODS:

Randomized intervention study. From 2015 to 2018, 16,660 participants (8,330 in the intervention group (Mobile Unit Follow-up Group) and 8,330 in the no intervention group (Electronic Medical History Follow-up Group )) aged between 45 and 70 years without a previous history of cardiovascular disease and with at least one cardiovascular risk factor will be randomly selected across the province of Lleida, Spain.

Read the detailed description

STUDY DESIGN AND POPULATION:

Randomized interventional study. From 2015 to 2018, 16,660 participants (8,330 in the intervention group (Mobile Unit Follow-up Group) and 8,330 in the no intervention group (Electronic Medical History Follow-up Group)) aged between 45 and 70 years without a previous history of cardiovascular disease and with at least one cardiovascular risk factor will be randomly selected across the province of Lleida, Spain. The Ethics Committee of the University Hospital Arnau de Vilanova in Lleida (Spain) approved the protocol. All patients signed informed consent. The study was conducted according to the principles of the Declaration of Helsinki.

SOURCE OF INFORMATION AND INSTRUMENTS FOR DATA COLLECTION:

In the Mobile Unit (MU), clinical, sociodemographic and anthropometric data will be recorded. Patients will be evaluated with artery ultrasound (carotid, femoral, transcranial and abdominal aorta), ankle-brachial index, pulse wave velocity, spirometry, determination of advanced glycation-end products, atrial fibrillation screening, dried blood spot test and urine analysis. Moreover, DNA, RNA, Saliva, blood and urine samples will be collected and stored in the biobank to identify new biomarkers using omic studies. Additionally, climate, air pollutant and airborne pollen data form the entire province of Lleida will be registered. In addition, variables such as physical exercise, diet and daytime will be collected.

In the no intervention group (Electronic Medical History Follow-up Group), participants will be followed through their electronic medical records. Sociodemographic (age, sex, race, marital status, education and labour status), clinical and anthropometric data and will be electronically collected.

PARTICIPANT SELECTION:

From a total of 410,246 people with an open history in the e-CAP (in October 24, 2014), the study population that meets the inclusion criteria will be identified. Of these, a total of 16,660 people (8,330 in the intervention group and 8,330 in the no intervention group) will be selected through simple randomization without replacement, within clusters defined by basic healthcare area, primary care (PC) centre or doctor's office, in accordance with the total number of people who may be visited in the MU during one year period. The participants of the selected intervention group will be informed of the study objectives and the diagnostic tests.

FOLLOW-UP PERIOD:

A minimum 10-year follow-up period has been established to observe the onset of CV events. In the Mobile Unit Follow-up group, a second visit will be performed after four year of recruitment.

CARDIOVASCULAR EVENTS AND CKD PROGRESSION:

The onset of a CV event will be recorded according to the 10th version of the International Statistical Classification of Diseases (ICD-10), which includes: angina pectoris, myocardial infarction, transient ischemic attack, cerebrovascular accident, heart failure, arrhythmia, peripheral artery disease, aortic aneurysm, revascularization and angioplasty of any artery region. Likewise, the patient's cause of death, whether of CV origin (myocardial infarction, arrhythmia, heart failure, cerebrovascular accident, aortic aneurysm, mesenteric infarction or sudden death) or of non-CV origin (infections, cancers, accident or kidney disease) will be recorded. The information sources used to identify CV events will be: review of medical records (through the e-CAP) and consultation of the Catalonia mortality registry. CKD progression is defined as a doubling of creatinine or entry into renal replacement therapy, and will also be collected through the e-CAP.

CLINICAL AND BIOCHEMICAL DATA:

The following variables will be recorded: weight, height, waist circumference and neck circumference, body mass index in kg/m2, hours of fasting, systolic blood pressure, diastolic blood pressure and pulse pressure (mmHg). Blood pressure will be measured 3 times (Omron 6®) at 2-min intervals and the mean of the last 2 will be collected. Dried capillary blood testing (fingertip puncture) will be used to determine creatinine, uric acid and total cholesterol, using the reflotron® Plus system (Roche). In cases in which total cholesterol is greater than 200 mg/dl, the complete lipid profile (HDL cholesterol, LDL cholesterol and triglycerides) will be determined using Cobas B 101® system, Roche. Non-HDL cholesterol levels, glycated hemoglobin (Cobas B 101 system, Roche), the CKD-EPI glomerular filtration rate will be determined as well. Albuminuria and albumin/creatinine ratio will be determined in urine sample from spontaneous micturition collected in the MU using Clinitek Microalbumin 2 Reagent Strips and a Siemens Clinitek Status® analyzer.

ARTERY ULTRASOUND:

The examination and reading will be performed by 2 nurses specialized in vascular imaging diagnostics, following a standardized protocol with the patient in supine decubitus. The VIVID I version BT12 ultrasound system (GE Healthcare) will be used. The system has a 12L-RS/4-13 MHz linear probe (carotid and femoral arteries), a 4C-RS/1.5-6 MHz convex probe (abdominal aorta) and a 3SRS/ 1.5-2.5 MHz sector probe (transcranial). It also has a module for measuring intima-media thickness and pulsed Doppler ultrasound to assess hemodynamic abnormalities in the case that atheromatous plaques are present, and also to analyze the intracranial circulation. The DICOM network connectivity system will be used to record the results and ultrasound images online in the e-CAP.

Carotid arteries: a total of 8 vascular regions will be analyzed (common carotid, bifurcation or bulb, internal carotid and external carotid), with the patient in supine decubitus and the head turned 45º towards the opposite side in the examination.

Femoral arteries: with the patient in supine decubitus, the presence of plaque will be examined in the common femoral artery (1 cm proximal to the bifurcation) and the superficial femoral artery on both sides. The plaque definition follows the same previous criteria.

Abdominal aorta: in men age 60 and older. With the patient in supine decubitus, the abdominal aorta will be examined in the midline of the abdomen from the base of the sternum until the bifurcation the iliac arteries. In an axial section, at the points where a greater diameter is observed, 2 images of the aorta will be captured, and 2 measurements will be made (anterior-posterior and lateral-lateral). An aortic aneurysm will be considered to be present when the diameter is greater than 3 cm.

Transcranial ultrasound: the arteries of the Willis circle and their branches will be insonated through the transtemporal and transforaminal acoustic windows. The Doppler spectrum of each intracranial artery will be determined using the colour-coded signal. Flow direction, peak systolic velocity, mean flow velocity and diastolic flow velocity will be established. The intracranial carotid artery, the medial cerebral artery in the M1 and M2 segments, the anterior cerebral artery (segment A1) and the posterior cerebral artery in segments P1 and P2 will be studied through the transtemporal acoustic window. The V4 segment of the vertebral arteries and the basilar artery will be studied through the transforaminal acoustic window. In each patient, the number, location and severity of stenosis will be recorded. Baumgartner's criteria will be used to establish the severity of the stenosis based on peak systolic wave velocity (moderate to serious stenosis, if it is ≥155/ 220 cm/s for the medial cerebral artery, ≤120/≥155 cm/s for the anterior cerebral artery, ≥100/≥145 cm/s for the posterior cerebral artery and the basilar artery, and ≥90/≥120 cm/s for the vertebral artery).

ANKLE-BRACHIAL INDEX:

A continuous Doppler (Hadecco ES100X MiniDop®), sphygmomanometer and blood pressure cuffs (Riester minimus III®) will be used. Systolic blood pressure will be measured in the brachial artery, posterior tibial artery and dorsalis pedis artery in both limbs. The ratios between tibial and pedal systolic blood pressure in each leg and the higher brachial blood pressure will be calculated. The final value for each limb will be the lower value of those obtained between tibial and pedal blood pressure. An ankle-brachial index value \<0.9 will be considered to be suggestive of stenosis; a value \<0.7 will be considered to be stenosis and a value ≥1.4 will be considered to be suggestive of arterial rigidity.

SPIROMETRY:

Spirometry will be used to assess lung capacity. It will be performed by the same nurse who will measure forced vital capacity (FVC); forced expiratory volume in one second (FEV1); the ratio between FEV1 and FVC and the lower limit of normality, as a percentage.

DETERMINATION OF ADVANCED GLYCATION-END PRODUCTS:

They will be measured using skin autofluorescence (SAF) in the forearm with the AGE Reader system® (Diagnostics, the Netherlands). SAF is measured using spectrophotometry which is calculated as the relationship of the intensity of reflected light compared to refracted light. The result obtained will be divided into 4 CV risk groups, taking into account age and sex.

ATRIAL FIBRILLATION SCREENING:

The presence of atrial fibrillation will be assessed with the SRA device® (EVINA Health Solutions) for one hour in the MU.

PULSE WAVE VELOCITY:

Pulse wave velocity (PWV) will be used as an indicator of arterial stiffness. It will be measured non-invasively with the carotid to femoral PWV (cfPWV) according to standard protocols.

BIOLOGICAL SAMPLE COLLECTION:

Blood samples from a peripheral vein of the hand or forearm to obtain serum, plasma, DNA and RNA will be collected. Moreover, a saliva sample will be collected.These samples will be prepared in aliquots following a standardized protocol, and sent frozen (dry ice) to a centralized biobank (IRBLleida Biobank, Spain) for processing and storage for subsequent studies of CV, inflammatory and mineral-metabolism biomarkers and genetic polymorphisms. Urine samples will be frozen and stored in a biobank for subsequent study of biomarkers.

STATISTICAL ANALYSIS:

Descriptive analysis will include absolute and relative frequencies for the qualitative variables, means and standard deviations for the continuous variables that follow a normal distribution, and median and interquartile range in the cases that do not follow a normal distribution. Their distribution will be analyzed with the chi-squared test, in the case of qualitative variables, and Student's t test or ANOVA for quantitative variables with a normal distribution, or, failing this, non-parametric Mann-Whitney U or Kruskal-Wallis tests will be used for those without a normal distribution. The correlation between quantitative variables will be analyzed using Pearson's or Spearman's test, depending on the distribution. The existence of collinearity between 2 variables will be analyzed to enter the variable that better predicts the result variable in the multivariate model. Multivariate analysis will be performed using logistic regression if the dependent variable is qualitative or linear regression if it is quantitative. Beta regression coefficients, odds ratios (ORs) and their respective 95% confidence intervals will be estimated as measures of association. In the longitudinal study, the incidence of CV morbidity and mortality and mortality due to any cause will be analyzed, based on the diagnostic tests used in the MU and the biomarkers studied using Cox regression. Statistical significance will be set at a p value \< 0.05.

03

Conditions studied

  • Atherosclerosis
  • Chronic Kidney Diseases
  • Metabolic Syndrome
  • PreDiabetes
  • Subclinical Disease and/or Syndrome

Keywords

  • Kidney Diseases
  • Subclinical Disease and/or Syndrome
  • Atherosclerosis
  • Biomarkers
  • Prevention
  • Lung capacity
  • Early diagnosis
  • Advanced glycation-end products
  • Atrial fibrillation
  • Diabetes
  • Arterial ultrasound
04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women (50-70 years) and men ( 45-65 years) with at least one cardiovascular risk factor (hypertension, dyslipidemia, obesity ( >30 Kg/m2), current smoking habit or former smoker (\<10 years), first-degree family history of early cardiovascular disease).

Exclusion criteria

Exclusion Criteria:

  • Prior medical history of cardiovascular disease.
  • Diabetes.
  • (CKD-EPI \< 60 ml/min/1.73m2).
  • Active neoplasm or acute disease.
  • A \< 18 months.
  • Pregnancy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16,660 participants (actual)

Study arms

  • Experimental
    Mobile Unit Follow-up Group

    In the Mobile Unit (MU), clinical, sociodemographic and anthropometric data will be recorded. Patients will be evaluated with artery ultrasound (carotid, femoral, transcranial and abdominal aorta), ankle-brachial index, pulse wave velocity, spirometry, determination of advanced glycation-end products, atrial fibrillation screening, dried blood spot test and urine analysis. Moreover, DNA, RNA, Saliva, blood and urine samples will be collected and stored in the biobank to identify new biomarkers using omic studies. Additionally, climate, air pollutant and airborne pollen data form the entire province of Lleida will be registered. Finally, a report with the exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.

    Diagnostic Test: Dried blood spot test · Diagnostic Test: Urine test · Diagnostic Test: Artery ultrasound · Diagnostic Test: Ankle-brachial index · Diagnostic Test: Spirometry · Diagnostic Test: Determination of advanced glycation-end products · Diagnostic Test: Atrial fibrillation screening · Other: Biological sample collection · Other: Result and recommendation report · Diagnostic Test: Pulse wave velocity

  • No intervention
    Electronic Medical History Follow-up Group

    Participants will be followed through their electronic medical records. Sociodemographic (age, sex, race, marital status, education and labour status), clinical and anthropometric data and will be electronically collected.

Interventions

  • Diagnostic testDried blood spot test

    Dried capillary blood testing creatinine, uric acid and total cholesterol (reflotron® Plus system, Roche). Determination of the complete lipid profile in cases in which total cholesterol is greater than 200 mg/dl: HDL cholesterol (mg/dl), LDL cholesterol (mg/dl) and triglycerides (mg/dl) (Cobas B 101® system, Roche). Calculation of non-HDL cholesterol levels. Glycated haemoglobin will be analysed with the Cobas B 101 system,Roche. The CKD-EPI glomerular filtration rate will be determined.

  • Diagnostic testUrine test

    A urine sample from spontaneous micturition will be collected and analyzed using Clinitek Microalbumin 2 Reagent Strips and a Siemens Clinitek Status® analyzer. It will be determined albuminuria (mg/l) and albumin/creatinine ratio (mg/g).

  • Diagnostic testArtery ultrasound

    Carotid and femoral artery ultrasound for atheroma plaque diagnosis. Abdominal aorta ultrasound for early diagnosis of aortic aneurism. Transcranial ultrasound for cerebral arterial blood flow alterations.

  • Diagnostic testAnkle-brachial index

    Systolic blood pressure measurement in the brachial artery, posterior tibial artery and dorsalis pedis artery in both limbs. The ratios between tibial and pedal systolic blood pressure in each leg and the higher brachial blood pressure will be calculated.

  • Diagnostic testSpirometry

    Spirometry will be used to assess lung capacity. It will be performed by the same nurse who will measure forced vital capacity (FVC); forced expiratory volume in one second (FEV1); the ratio between FEV1 and FVC and the lower limit of normality, as a percentage.

  • Diagnostic testDetermination of advanced glycation-end products

    These will be measured using skin autofluorescence (SAF) in the forearm with the AGE Reader® system (Diagnostics, the Netherlands). SAF is measured using spectrophotometry which is calculated as the relationship of the intensity of reflected light compared to refracted light.

  • Diagnostic testAtrial fibrillation screening

    The presence of atrial fibrillation is assessed with a device (SRA, EVINA Health Solutions) during one hour in the mobile unit.

  • OtherBiological sample collection

    Blood samples from a peripheral vein of the hand or forearm to obtain serum, plasma, DNA and RNA will be collected. Moreover, a saliva sample will be collected.These samples will be prepared in aliquots following a standardized protocol, and sent frozen (dry ice) to a centralized biobank (IRBLleida Biobank, Spain) for processing and storage for subsequent studies of CV, inflammatory and mineral-metabolism biomarkers and genetic polymorphisms. Urine samples will be frozen and stored in a biobank for subsequent study of biomarkers.

  • OtherResult and recommendation report

    A report with exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.

  • Diagnostic testPulse wave velocity

    Pulse wave velocity (PWV) will be used as an indicator of arterial stiffness. It will be measured non-invasively with the carotid to femoral PWV (cfPWV) according to standard protocols.

06

What researchers measure

Primary outcomes

  1. Identification of sociodemographic, lifestyle, clinical, anthropometric, laboratory, climate and air pollutants factors involved in atherosclerosis, in a low/moderate cardiovascular risk population.

    The presence of atherosclerosis will be identified as an intima-media thickness higher than 1.5 mm.

    Time frame: 4 years

  2. Identification of sociodemographic, lifestyle, clinical, anthropometric, laboratory, climate and air pollutants factors involved in pre-diabetes, in a low/moderate cardiovascular risk population.

    The percentage of glycated hemoglobin (Hb A1c) will be determined with a Cobas b 101® machine (Roche). Values lower than 5.7% are normal, \> 5.7-6.5% indicate pre-diabetes; and ≥ 6.5% indicate diabetes.

    Time frame: 4 years

  3. Identification of sociodemograpic, lifestyle, clinical, anthropometric, laboratory, climate and air pollutants factors involved in chronic kidney disease, in a low/moderate cardiovascular risk population.

    The prevalence of hidden chronic kidney disease will be assessed with a urine spot test that determines the albumin/creatinine ratio (ACR). Values lower than 30 mg/g are normal; 30-300 mg/g indicate microalbuminuria; and values higher than 300 indicate macroalbuminuria.

    Time frame: 4 years

  4. Assessment of the impact of arterial ultrasound on cardiovascular events and mortality in a low/moderate cardiovascular risk population.

    The onset of a cardiovascular event will be recorded according to the tenth version of the International Statistical Classification of Diseases (ICD-10). Cardiovascular events and mortality in the intervention group will be compared to the control group during a during a 10-year follow-up period.

    Time frame: 10 years

Secondary outcomes

  1. Prevalence of atherosclerosis in a low/moderate cardiovascular risk population

    The presence of atherosclerosis will be identified as an intima-media thickness higher than 1.5 mm.

    Time frame: 4 years

  2. Prevalence of hidden chronic kidney disease in a low/moderate cardiovascular risk population.

    The prevalence of hidden chronic kidney disease will be assessed with a urine spot test that determines the albumin/creatinine ratio (ACR). Values lower than 30 mg/g are normal; 30-300 mg/g indicate microalbuminuria; and values higher than 300 indicate macroalbuminuria.

    Time frame: 4 years

  3. Prevalence of pre-diabetes and undiagnosed diabetes in a low/moderate cardiovascular risk population.

    The percentage of glycated hemoglobin (Hb A1c) will be determined with a Cobas b 101® machine (Roche). Values lower than 5.7% are normal; 5.7-6.5% indicate pre-diabetes; and ≥ 6.5% indicate diabetes.

    Time frame: 4 years

  4. Correlation of skin autofluorescence with atherosclerosis in a low/moderate cardiovascular risk population.

    Skin autofluorescence will be analyzed with the AGE reader™ device (DiagnOptics Technologies, Groningen, The Netherlands). Values range from 1-24 units.

    Time frame: 4 years

  5. Correlation of adherence to the Mediterranean diet with atherosclerosis in a low/moderate cardiovascular risk population.

    Adherence to the Mediterranean diet will be evaluated with the Mediterranean Diet Adherence screener (MEDAS). Values are from 0 to 14 and categorize subjects according to their level of adherence: high (score \>11 points), moderate (7-10 points), and low (\<6 points).

    Time frame: 4 years

  6. Correlation of physical exercise with atherosclerosis in a low/moderate cardiovascular risk population.

    Physical exercise will be evaluated with the International Physical Activity Questionnaire (IPAQ). Values are from vigorous, moderate, and low physical activity. Low activity corresponds to no activity or some activity but not enough to meet moderate category. Moderate corresponds to 3 or more days of walking for at least 30 minutes. Vigorous activity corresponds to 5 or more days of walking for at least 60 minutes.

    Time frame: 4 years

  7. Prevalence of atrial fibrillation in a low/moderate cardiovascular risk population.

    The presence of atrial fibrillation is assessed with stroke risk analysis device (SRA, EVINA Health Solutions).

    Time frame: 4 years

  8. Correlation of spirometry alterations with atherosclerosis in a low/moderate cardiovascular risk population

    Forced vital capacity (FVC) will be measured as liters (l).

    Time frame: 4 years

  9. Correlation of advanced glycation end-products (AGEs) and cardiovascular events in a low/moderate cardiovascular risk population.

    AGES will be analyzed with the AGE reader™ device (DiagnOptics Technologies, Groningen, The Netherlands). Values range from 1-24 units.

    Time frame: 10 years

  10. Correlation of adherence to the Mediterranean diet and cardiovascular events in a low/moderate cardiovascular risk population.

    Adherence to the Mediterranean diet will be evaluated with the Mediterranean Diet Adherence screener (MEDAS). Values are from 0 to 14 and categorize subjects according to their level of adherence: high (score \>11 points), moderate (7-10 points), and low (\<6 points).

    Time frame: 10 years

  11. Correlation of physical exercise and cardiovascular events in a low/moderate cardiovascular risk population.

    Physical exercise will be evaluated with the International Physical Activity Questionnaire (IPAQ). Values are from vigorous, moderate, and low physical activity.

    Time frame: 10 years

  12. Association of spirometry alterations and cardiovascular events in a low/moderate cardiovascular risk population

    Forced vital capacity (FVC) will be measured as liters (l).

    Time frame: 10 years

07

Study locations

3 sites
  • Fundació Renal Jaume Arnò
    Lleida, Lleida 25006, Spain
  • Primary Care centre
    Lleida, Lleida 25007, Spain
  • Institut de recerca Biomèdica de Lleida
    Lleida, Lleida 25198, Spain
08

References and documents

Publications

  • Betriu A, Farras C, Abajo M, Martinez-Alonso M, Arroyo D, Barbe F, Buti M, Lecube A, Portero M, Purroy F, Torres G, Valdivielso JM, Fernandez E. Randomised intervention study to assess the prevalence of subclinical vascular disease and hidden kidney disease and its impact on morbidity and mortality: The ILERVAS project. Nefrologia. 2016 Jul-Aug;36(4):389-96. doi: 10.1016/j.nefro.2016.02.008. Epub 2016 Apr 1. English, Spanish. PubMed 27044887 ↗
  • Sanchez E, Lecube A, Betriu A, Hernandez C, Lopez-Cano C, Gutierrez-Carrasquilla L, Kerkeni M, Yeramian A, Purroy F, Pamplona R, Farras C, Fernandez E, Barbe F, Simo R; ILERVAS project; Hernandez M, Rius F, Polanco D, de la Torre MS, Torres G, Godoy P, Portero-Otin M, Jove M, Colas-Compas L, Benabdelhak I, Miquel E, Ortega M, Valdivielso JM, Bermudez M, Martinez-Alonso M. Subcutaneous advanced glycation end-products and lung function according to glucose abnormalities: The ILERVAS Project. Diabetes Metab. 2019 Dec;45(6):595-598. doi: 10.1016/j.diabet.2018.04.002. Epub 2018 Apr 13. No abstract available. PubMed 29706471 ↗
  • Montserrat-Capdevila J, Seminario MA, Godoy P, Marsal JR, Ortega M, Pujol J, Castan MT, Alseda M, Betriu A, Lecube A, Portero M, Purroy F, Valdivielso JM, Barbe F. Prevalence of chronic obstructive pulmonary disease (COPD) not diagnosed in a population with cardiovascular risk factors. Med Clin (Barc). 2018 Nov 21;151(10):383-389. doi: 10.1016/j.medcli.2017.12.018. Epub 2018 Mar 7. English, Spanish. PubMed 29525115 ↗
  • Gutierrez-Carrasquilla L, Sanchez E, Hernandez M, Polanco D, Salas-Salvado J, Betriu A, Gaeta AM, Carmona P, Purroy F, Pamplona R, Farras C, Lopez-Cano C, Fernandez E, Lecube A. Effects of Mediterranean Diet and Physical Activity on Pulmonary Function: A Cross-Sectional Analysis in the ILERVAS Project. Nutrients. 2019 Feb 3;11(2):329. doi: 10.3390/nu11020329. PubMed 30717453 ↗
  • Sanchez E, Betriu A, Yeramian A, Fernandez E, Purroy F, Sanchez-de-la-Torre M, Pamplona R, Miquel E, Kerkeni M, Hernandez C, Simo R, Lecube A; ILERVAS project; ILERVAS Project:; Hernandez M, Rius F, Polanco D, Barbe F, Torres G, Suarez G, Portero-Otin M, Jove M, Colas-Campas L, Benabdelhak I, Farras C, Ortega M, Manuel Valdivielso J, Bermudez-Lopez M, Martinez-Alonso M. Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project. J Atheroscler Thromb. 2019 Oct 1;26(10):879-889. doi: 10.5551/jat.47498. Epub 2019 Mar 6. PubMed 30842389 ↗
  • Sanchez E, Gutierrez-Carrasquilla L, Barbe F, Betriu A, Lopez-Cano C, Gaeta AM, Purroy F, Pamplona R, Ortega M, Fernandez E, Hernandez C, Lecube A, Simo R; ILERVAS Project. Lung function measurements in the prediabetes stage: data from the ILERVAS Project. Acta Diabetol. 2019 Sep;56(9):1005-1012. doi: 10.1007/s00592-019-01333-6. Epub 2019 Apr 15. PubMed 30989377 ↗
  • Sanchez E, Betriu A, Salas-Salvado J, Pamplona R, Barbe F, Purroy F, Farras C, Fernandez E, Lopez-Cano C, Mizab C, Lecube A; ILERVAS project investigators. Mediterranean diet, physical activity and subcutaneous advanced glycation end-products' accumulation: a cross-sectional analysis in the ILERVAS project. Eur J Nutr. 2020 Apr;59(3):1233-1242. doi: 10.1007/s00394-019-01983-w. Epub 2019 May 7. PubMed 31065845 ↗
  • Sanchez M, Sanchez E, Hernandez M, Gonzalez J, Purroy F, Rius F, Pamplona R, Farras-Salles C, Gutierrez-Carrasquilla L, Fernandez E, Bermudez-Lopez M, Salvador J, Salas-Salvado J, Lecube A; ILERVAS project collaborators. Dissimilar Impact of a Mediterranean Diet and Physical Activity on Anthropometric Indices: A Cross-Sectional Study from the ILERVAS Project. Nutrients. 2019 Jun 17;11(6):1359. doi: 10.3390/nu11061359. PubMed 31212934 ↗
  • Leon-Mengibar J, Malagon MM, Bermudez-Lopez M, Valdivielso JM, Pamplona R, Torres G, Mauricio D, Castro E, Fernandez E, Caixas A, Hernandez M, Lopez-Cano C, Gordon A, Guzman-Ruiz R, Cusi K, Lecube A. Association of estimated liver fibrosis with carotid but not femoral atherosclerotic burden: the ILERVAS cohort. Front Endocrinol (Lausanne). 2026 Jan 6;16:1651689. doi: 10.3389/fendo.2025.1651689. eCollection 2025. PubMed 41567808 ↗
  • Leon-Mengibar J, Bermudez-Lopez M, Valdivielso JM, Pamplona R, Torres G, Mauricio D, Castro-Boque E, Fernandez E, Caixas A, Bueno M, Ciudin A, Hernandez M, Simo R, Hernandez C, Lecube A. Impact of the new EASO obesity definition on the detection of atheromatosis in subjects with low-to-moderate cardiovascular risk. Front Endocrinol (Lausanne). 2025 Oct 10;16:1689960. doi: 10.3389/fendo.2025.1689960. eCollection 2025. PubMed 41141356 ↗
  • Bermudez-Lopez M, Marti-Antonio M, Castro-Boque E, Bretones MDM, Farras C, Torres G, Pamplona R, Lecube A, Mauricio D, Valdivielso JM, Fernandez E. Development and Validation of a Personalized, Sex-Specific Prediction Algorithm of Severe Atheromatosis in Middle-Aged Asymptomatic Individuals: The ILERVAS Study. Front Cardiovasc Med. 2022 Jul 14;9:895917. doi: 10.3389/fcvm.2022.895917. eCollection 2022. PubMed 35928938 ↗
  • Bermudez-Lopez M, Martinez-Alonso M, Castro-Boque E, Betriu A, Cambray S, Farras C, Barbe F, Pamplona R, Lecube A, Mauricio D, Purroy F, Valdivielso JM, Fernandez E; ILERVAS project collaborators. Subclinical atheromatosis localization and burden in a low-to-moderate cardiovascular risk population: the ILERVAS study. Rev Esp Cardiol (Engl Ed). 2021 Dec;74(12):1042-1053. doi: 10.1016/j.rec.2020.09.015. Epub 2020 Nov 6. English, Spanish. PubMed 33162389 ↗
  • Sanchez E, Betriu A, Lopez-Cano C, Hernandez M, Fernandez E, Purroy F, Bermudez-Lopez M, Farras-Salles C, Barril S, Pamplona R, Rius F, Hernandez C, Simo R, Lecube A; ILERVAS project collaborators. Characteristics of atheromatosis in the prediabetes stage: a cross-sectional investigation of the ILERVAS project. Cardiovasc Diabetol. 2019 Nov 15;18(1):154. doi: 10.1186/s12933-019-0962-6. PubMed 31729979 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Dec 2018, 47 months.

Of 178 non-industry interventional studies with no phase under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 47 months is above that.

Counting every sponsor, half of 198 studies reached it within 30 months; a quarter within 17 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2017
First posted
Jul 25, 2017
StartActual
Jan 15, 2015
Primary completionActual
Dec 31, 2018
CompletionEst.
Dec 31, 2028
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03228459
Lead sponsor
Institut de Recerca Biomèdica de Lleida
Collaborators
Diputació de Lleida, Jaume Arnó Renal Foundation, Unit of Detection and Treatment of Atherothrombotic diseases (UDETMA), Lleida Primary health care
Responsible party
Elvira Fernández Giráldez (Study Chair, Institut de Recerca Biomèdica de Lleida) — Principal investigator
First posted
Jul 25, 2017
Start date
Jan 15, 2015
Primary completion
Dec 31, 2018
Completion
Dec 31, 2028 (estimated)
Last update
Mar 27, 2026

Study contacts

Elvira Fernández Giráldez, MD, PhD
study chair · Fundació Renal Jaume Arnò
Marcelino Bermúdez López, MD, PhD
study director · Institut de Recerca Biomèdica de Lleida

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion